Our results contrast with those reported by Taparra et al., who observed an increase in SA-β-galactosidase activity in H358, A549, and H460 lung cancer cells following pharmacological inhibition of GFAT or OGT, both in vitro and in xenograft experiments [31]. The gene discussed is GFPT2; the disease is lung cancer.